Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTL-101 in relapsed/refractory multiple myeloma (Phase I/II)
CTR20261523Phase 2Active
- Sponsor
- Bendo Biotech
- Start
- Apr 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BTL-101 in multiple myeloma (MM), sponsored by Bendo Biotech. Started Apr 2026; status: active.
02
Drugs
BTL-101
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20261523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261523.